Revelation Biosciences (FRA:56U0) Additional Paid-In Capital : €34.61 Mil(As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Additional Paid-In Capital?

Revelation Biosciences's quarterly additional paid-in capital declined from Sep. 2023 (€30.06 Mil) to Dec. 2023 (€29.45 Mil) but then increased from Dec. 2023 (€29.45 Mil) to Mar. 2024 (€34.61 Mil).

Revelation Biosciences's annual additional paid-in capital increased from Dec. 2021 (€12.76 Mil) to Dec. 2022 (€24.92 Mil) and increased from Dec. 2022 (€24.92 Mil) to Dec. 2023 (€29.45 Mil).

Revelation Biosciences Additional Paid-In Capital Historical Data

The historical data trend for Revelation Biosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Additional Paid-In Capital Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

4.55

12.76

24.92

29.45

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial								27.27	29.58	30.06	29.45	34.61

Revelation Biosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Revelation Biosciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines